Posted by Michael Wonder on 27 Oct 2021
Moderna announces Swissmedic authorises booster dose of Moderna’s COVID-19 vaccine
26 October 2021 - Authorisation granted for particularly vulnerable individuals 12 years of age and older.
Moderna today announced Swissmedic has authorised a booster dose of Spikevax, the Company’s vaccine against COVID-19, at the 50 µg dose level in particularly vulnerable individuals 12 years of age and older, at least six months after completion of the primary series.
Swissmedic also approved a third dose of Spikevax at the 100 µg dose level for people with a weakened immune system at least 28 days after the second dose.
